Unknown

Dataset Information

0

An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.


ABSTRACT: C2-8 is a small molecule inhibitor of polyglutamine aggregation and can reduce photoreceptor neurodegeneration in a Drosophila model of Huntington's disease (HD). Further preclinical studies have shown that oral administration of C2-8 in R6/2 HD transgenic mice can penetrate into the brain, reduce mHTT-exon1 aggregation, improve motor performance and diminish striatal neuron atrophy.In this independent preclinical study, we aimed to evaluate the pharmacokinetic properties and therapeutic efficacy of C2-8 intraperitoneal (IP) delivery in the R6/2 HD mouse.R6/2 mice were IP injected with low dose C2-8 (10 mg/kg), high dose C2-8 (20 mg/kg), or vehicle twice daily from 3 weeks to 3 months old. Longitudinal behavioral tests (accelerating Rotarod and wire-hang) were performed to evaluate the motor deficits, and neuropathology was measured by unbiased stereology.We confirmed that the compound has good blood-brain-barrier penetration after acute or sub-chronic intraperitoneal delivery. Chronic treatment with C2-8 in R6/2 mice results in a significant reduction of nuclear mHTT aggregate volume in the brains, replicating a key finding of C2-8 as a polyglutamine aggregation inhibitor in vivo. However, by comparing HD mice with C2-8 treatment to those with vehicle treatment, we were unable to demonstrate significant amelioration of motor deficits using Rotarod and wire-hang tests. Moreover, we did not observe improvement in the striatal neurodegenerative pathology, as measured by brain weight, striatal volume, and striatal neuron volume in the C2-8 treated R6/2 mice.Our study supports the practice of independent preclinical studies for novel molecules in HD therapeutic development and suggests that the use of alternative delivery strategies and full-length HD mouse models are likely needed to further assess whether the aggregate-inhibiting properties of C2-8 can be consistently translated into a preclinical benefit in HD mice.

SUBMITTER: Wang N 

PROVIDER: S-EPMC4124458 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.

Wang Nan N   Lu Xiao-Hong XH   Sandoval Susana V SV   Yang X William XW  

Journal of Huntington's disease 20130101 4


<h4>Background</h4>C2-8 is a small molecule inhibitor of polyglutamine aggregation and can reduce photoreceptor neurodegeneration in a Drosophila model of Huntington's disease (HD). Further preclinical studies have shown that oral administration of C2-8 in R6/2 HD transgenic mice can penetrate into the brain, reduce mHTT-exon1 aggregation, improve motor performance and diminish striatal neuron atrophy.<h4>Objective</h4>In this independent preclinical study, we aimed to evaluate the pharmacokinet  ...[more]

Similar Datasets

| S-EPMC2034257 | biostudies-literature
| S-EPMC3043604 | biostudies-literature
| S-EPMC6886799 | biostudies-literature
| S-EPMC4992622 | biostudies-literature
| S-EPMC3770591 | biostudies-literature
| S-EPMC7831778 | biostudies-literature
| S-EPMC8487039 | biostudies-literature
| S-EPMC3502570 | biostudies-literature
| S-EPMC4461140 | biostudies-literature
| S-EPMC3721540 | biostudies-literature